Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo and in vitro

• J. Yu ^[1] ; Y. Zhao ^[1] ; C. Liu ^[1] ; B. Hu ^[2] ; M. Zhao ^[1] ; Y. Ma ^[1] ; J. Jiang ^[1]
  1. [1] Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University, Yichang, China
  2. [2] Department of Ultrasonography, The Second Clinical Medical College of China, Three Gorges University, Yichang, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 1, 2020, págs. 60-69
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • PurposeImproved therapeutic options for cervical cancer are needed. The purpose of this study was to evaluate the syn-ergetic, inhibitory effects of ultrasound-mediated paclitaxel (PTX)- and miR-34a-loaded microbubbles (MBs) on cervical cancer.MethodsU14 cervical cancer cells and xenograft mouse tumors were treated with PTX-miR-34a-MBs.ResultsLevels of miR-34a increased in vitro and vivo after treatment with ultrasound-mediated PTX-miR-34a-MBs. Fur-thermore, this treatment decreased the proliferation of cervical cancer cells, microvessel density, and the expression of Bcl-2 and CDK6, both in vitro and in vivo. Furthermore, Bax expression was increased in the in vivo model. And, tumor volume and weight were significantly reduced by 78.57% and 87.97%, respectively (P < 0.01).ConclusionsThese results indicate that ultrasound-mediated PTX-miR-34a-MBs synergistically inhibit the growth of cervical cancer via the upregulation of miR-34a and downregulation of Bcl-2 and CDK6. Thus, PTX-miR-34a-MBs in combination with ultrasound microbubbles are a promising anticancer delivery strategy for treating cervical cancer.